高脂肪餐增加了布隆纳的生物可用性,在中国的健康受试者中增加了5倍
Xue Sun1, Haojing Song1, Na Zhao1
1Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, 050051, People's Republic of China.
Drug design, development and therapy
|July 21, 2025
概括
在健康人群中,高脂肪饮食显著增加了约5倍的blonanserin生物可用性. 在食和禁食条件下,布隆南仍然是安全的,并且可以很好地耐受,这表明食物摄入不会改变其安全性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 药物新陈代谢 药物新陈代谢
背景情况:
- 布隆南塞林是一种广泛处方的抗精神病药物.
- 现有的研究表明,食物对布隆纳瑟林的药理动力学有不同的影响.
- 了解这些食物的影响对于优化临床剂量至关重要.
研究的目的:
- 为了研究食物对4毫克的布隆南塞林片药理学的影响.
- 评估blonanserin在被食和禁食条件下的安全性.
- 在健康的中国人中评估布隆纳塞林的生物可用性.
主要方法:
- 采用生物等价性研究设计,对106名健康受试者进行了研究.
- 被试被随机分为禁食和食 (高脂肪餐) 组.
- 使用验证的HPLC-MS/MS测量了血博朗塞林度,并分析了药理动力学参数.
主要成果:
- 一个高脂肪的饭菜增加了blonanserin的Cmax,AUC0-t和AUC0-∞大约5倍.
- 药物动力学参数的90%置信区间在生物等效范围之外.
- 药物不良反应在各组之间是相似的,通常是轻微的.
结论:
- 食物显著提高了blonanserin在4mg剂量中的生物可用性.
- 布隆南塞林在不考虑食物摄入的情况下表现出良好的安全性.
- 布隆纳林的临床剂量策略应考虑到重要的食物影响.
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
299
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
299
Cholinergic Antagonists: Pharmacokinetics
562
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
562
Factors Influencing Bioavailability: First-Pass Elimination
7.0K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
7.0K
Factors Affecting Drug Biotransformation: Biological
241
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
241
Bioavailability: Overview
3.1K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
3.1K


